Research progress on the novel glutaminase inhibitor and its antitumor activity

VernacularTitle:谷氨酰胺酶新型抑制剂及其抗肿瘤活性研究进展*
Author: Ying LIAO ¹ ; Linhua JI ; Sen CUI
Author Information

1. 青海大学附属医院血液内科(青海省西宁市810000
Keywords: glutamine metabolism; glutaminase; tumor,glutaminase inhibitor,CB-839
From: Chinese Journal of Clinical Oncology 2019;46(7):366-369
CountryChina
Language:Chinese
Abstract: Tumor cells use several metabolic pathways to support bioenergetic and biosynthetic demands of proliferation. In addition to glucose, glutamine is an important source of precursor substances and energy for cancer cell growth. Glutaminase (GSL) activity is associated with Ras, c-Myc, and other oncogenes, as well as Rho GTP enzyme. Many preclinical studies have confirmed that glutamin-ase inhibitors not only exhibit anti-tumor activity, but can also remarkably enhance the sensitivity of resistant cancer cells to targeted drugs. At present, the novel GSL inhibitor CB-839 has entered phase I clinical trials and is expected to become a new drug for cancer treatment. This paper reviews the research progress on this novel glutaminase inhibitor and its antitumor activity.